The correct quantification of intact AAV capsids is a prerequisite for safe and effective gene transfer. As the exclusive manufacturer of AAV antibodies and established AAV quantification ELISAs, PROGEN provides high-quality tools for gene therapy. Explore our digital booth to learn how our calibrated ELISAs measure accurate titers of the most commonly used AAV serotype capsids and how you can save time with the 2 hrs Xpress version. Check our posters, presentations and videos on latest advancements in AAV titer determination, standardization, or cell-based neutralization assays!
Get in touch with us any time during the conference and afterwards (info@progen.com)!
Agenda
Tuesday May 12, 4.15 - 4.30 pm: Tools & Technologies Forum Presentation "AAV Antibodies - Overview of Qualified Applications" by Dana Holzinger, Product Manager
Wednesday May 13, 5.30 - 6.30 pm: Poster Presentation #901 "AAV capsid antibodies as positive control for neutralization assays"
Thursday May 14, 5.30 - 6.30 pm: Poster Presentation #1295 "AAV Xpress ELISA - finish it faster"
Presenters
Caroline Odenwald
Marketing Communications Manager
Marketing Communications Manager since 2018. Caroline is responsible for the conception, planning and implementation of PROGEN´s marketing activities (e.g. articels, application notes & online marketing)
Dana Holzinger
Product Manager
Product Manager since 2019. Dana represents the interface between the in-house R&D and customer needs for the AAV Titration ELISAs and AAV antibodies.
Isabelle Hinner
Strategic Account Manager
Strategic Account Manager since 2019.
Isabelle is responsible for the establishment and maintenance of PROGEN´s international customer relationships, the cooperation with distributors and the identification of the customer requirements.
Katharina Hammer
Director Quality Control
Director Quality Control since 2016. Katharina is responsible for all quality relevant steps concerning the AAV ELISAs and is strongly involved in AAV analytics.
Ina Berger
Scientific Support Representative
Scientific Support Representative since 2016. Ina provides high-level technical support concerning all product-related question. As a biological PhD she possesses hands-on experience in the lab.
Katja Betts
CEO
CEO since 2019. Katja is a keen networker and always interested in setting up mutually beneficial collaborations that further the field of AAV gene therapy.
Hüseyin Besir
Director Research & Development
Director R&D since 2016
Hüseyin is responsible for developing new and reliable products as well as evaluating new technologies and tools for expanding PROGEN’s AAV portfolio.